摘要
目的:研究黄连苦寒成分对体内代谢过程的药性影响。方法:采用指纹图谱作为主要的表征手段,结合HPLC-UV技术,研究和比较体外药物图谱和体内血清图谱差异,分析黄连在体内直接作用的代谢物,讨论黄连给药后成分与传统疗效之间的关系,进一步明确其对苦寒药性的影响。结果:黄连煎煮液各成分经吸收入血后,可检出9种成分以及黄连残渣药材中检出3种成分,能够充分的证明黄连的药效物质成分具有苦寒药性。结论:黄连苦寒成分对体内过程药性具有一定的影响,并在一定程度上阐述了黄连的苦寒药性。
Objective： To evaluate the clinical efficacy of amiodarone in coronary heart disease（CHD） patients with chronic heart failure and ventricular arrhythmia. Methods： from November 2014 to November 2016 from 128 cases of chronic heart failure of CHD with ventricular arrhythmia were randomly divided into control group and observation group, 64 cases in control group were given; oxygen, lipid-lowering drug therapy, patients in the observation group based on the control group adding the use of amiodarone treatment; changes before and after treatment in clinical efficacy of two groups of patients ventricular extrasystole and the number of left ventricular ejection fraction were evaluated. Results： In the observation group after treatment, the total effective rate was 96.88% higher than that of control group of 71.88% （P〈 0.05）; in two group patients the former contractions and the number of left ventricular ejection fraction by comparison the two groups showed no significant difference（P〉0.05）, the observation group after treatment in patients with ventricular premature the contraction frequency was significantly lower than the control group, left ventricular ejection fraction was significantly higher than the control group（P〈0.05）. Conclusion： the use of amiodarone in the treatment of chronic heart failure of CHD with ventricular arrhythmia patients can significantly improve the heart function.
出处
《抗感染药学》
2017年第2期256-258,共3页
Anti-infection Pharmacy
关键词
黄连
药物成分
苦寒药性
体内代谢
Amiodarone
coronary heart disease
chronic heart failure
ventricular arrhythmia
